"The Future of Obesity Treatment: Exploring the Broad Impact of New Weight-Loss Drugs"
Weight-loss drugs containing semaglutide, like Novo Nordisk's Ozempic and Lilly's Mounjaro, are being explored for their potential benefits in treating a variety of health conditions beyond type 2 diabetes. These include chronic kidney disease, cardiovascular disease, neurological disorders such as Alzheimer's and Parkinson's, liver disease, sleep apnea, polycystic ovary syndrome (PCOS), knee osteoarthritis, and even alcohol addiction. The drugs are part of a class known as GLP-1 therapies, which are currently undergoing various stages of clinical trials to determine their efficacy in these new applications.